Catalog No.
Product Name
Application
Product Information
Citations
-
CCR4 Receptor Antagonist
AZD-1678 is a potent antagonist of the CCR4 receptor, exhibiting a pIC50 of 8.6. This compound demonstrates significant biological activity in inhibiting CCR4-mediated signaling pathways, making it useful for research focused on immune response modulation and cancer immunotherapy. Its specificity for the CCR4 receptor allows for detailed studies in related disease models, enhancing our understanding of targeted therapeutic strategies. -
CCR4 Antagonist
CCR4-351 is a potent and selective antagonist of the CCR4 receptor. With IC50 values of 22 nM and 50 nM in the calcium flux and CTX assays, respectively, this compound demonstrates significant biological activity. CCR4-351 is primarily utilized in research applications exploring its antitumor effects and potential therapeutic benefits in modulating immune responses. -
CCR8 Antibody
Tagmokitug (CHS-114) is a fully human IgG1 antibody that specifically targets the CCR8 receptor. This antibody is valuable for researching head and neck squamous cell carcinoma (HNSCC) and understanding the role of CCR8 in tumor microenvironments. Researchers can utilize Tagmokitug to investigate CCR8-mediated signaling pathways and their implications in cancer progression. -
CCR2/5 Antagonist
PF-04634817 succinate is a potent dual antagonist of the CCR2 and CCR5 receptors, demonstrating comparable efficacy in human and rodent CCR2 with an IC50 of 20.8 nM in rats, while exhibiting a reduced potency for CCR5 (IC50 of 470 nM). This compound is suitable for investigating the role of these receptors in various biological pathways, particularly in the context of diabetic nephropathy. PF-04634817 succinate is an important tool for researchers exploring inflammatory and fibrotic processes associated with chronic kidney disease. -
hCCR2 Inhibitor
JNJ-41443532 is a selective antagonist of the human CCR2 receptor, exhibiting an IC50 of 37 nM for binding and demonstrating potent functional antagonism with an IC50 of 30 nM in chemotaxis assays. This compound shows a Ki value of 9.6 µM for murine CCR2 binding. JNJ-41443532 is suitable for research into inflammatory diseases and related inflammatory pathways. -
CCR4 Antagonist
CCR4-351 hydrochloride is a selective antagonist of the CCR4 receptor. This compound exhibits potent biological activity with IC50 values of 22 nM in the calcium flux assay and 50 nM in the CTX assay. Its antagonistic properties make CCR4-351 hydrochloride a valuable tool for research in cancer biology and therapeutic development, particularly in exploring its antitumor effects. -
CCR2 Antagonist
JNJ-27141491 is a selective noncompetitive antagonist of the human chemokine receptor CCR2. It inhibits CCR2-mediated signaling, making it a valuable tool for studying immune responses and inflammation. This compound is useful in research applications focused on cardiovascular diseases and cancer, where CCR2 plays a significant role in immune cell recruitment and tissue remodeling. -
CCR5 Antagonist
AZD-5672 is a potent and selective antagonist of the CCR5 receptor, exhibiting an IC50 of 0.32 nM. This compound demonstrates moderate activity against the hERG ion channel with a binding IC50 of 7.3 μM and acts as a substrate for human P-glycoprotein, inhibiting P-gp-mediated digoxin transport with an IC50 of 32 μM. AZD-5672 is an effective tool for investigating the role of CCR5 in inflammatory diseases, including rheumatoid arthritis. -
CCR5 Antagonist
Met-RANTES (human) is a potent antagonist of the CCR5 chemokine receptor, demonstrating significant inhibitory activity against human MIP-1α and MIP-1β with IC50 values of 5 nM and 2 nM, respectively. This compound has been shown to effectively reduce bone destruction and improve symptoms in models of adjuvant-induced arthritis in rats. Its application in research may provide valuable insights into inflammatory pathways and therapeutic strategies for diseases involving CCR5 signaling. -
CCR2 Antagonist
(1S)-CCR2 antagonist 1 is a selective antagonist targeting the CCR2 receptor. It demonstrates high-affinity binding with a Ki value of 2.4 nM, indicating its potential effectiveness in modulating CCR2-mediated biological processes. This compound is primarily utilized in research applications focused on inflammation, neurodegenerative diseases, and cancer, where CCR2 signaling plays a significant role. Its long residence time enhances its suitability for in vivo studies and therapeutic developments. -
CCR4 Antagonist
CCR4 antagonist 3 is a selective antagonist of chemokine receptor 4 (CCR4) with an IC50 value of 1.7 μM for radiolabeled thymus and activation-regulated chemokine (TARC). This compound effectively inhibits the binding of TARC and macrophage-derived chemokine (MDC) to CCR4 receptors on CEM cell surfaces. Additionally, CCR4 antagonist 3 reduces the in vitro migration of CEM cells induced by TARC, with an IC50 of 6.4 μM. This reagent is valuable for studies investigating CCR4-related immune responses and potential therapeutic interventions in diseases involving CCR4 signaling. -
CCR2 Antagonist
BMS-681 is an orthosteric antagonist of the CC chemokine receptor 2 (CCR2). It effectively inhibits receptor activity by stabilizing transmembrane helix 7, thereby influencing the conformation of transmembrane helix 6, which is pivotal to the orthosteric binding site. This compound is valuable for research into inflammatory neurodegenerative diseases and cancer, allowing for investigations into CCR2-mediated signaling pathways and potential therapeutic interventions. -
CCR Antagonist
CCR1 antagonist 6 is a selective antagonist of chemokine receptor 1 (CCR1), exhibiting an impressive IC50 of 3 nM. This compound is instrumental in research applications focused on inflammatory responses and immune modulation. Its ability to inhibit CCR1 makes it a valuable tool for investigating the role of this receptor in various disease models, including autoimmune and chronic inflammatory disorders. -
CCR Antagonist
CCR1 antagonist 7 (compound 16r) is a selective antagonist of chemokine receptor 1 (CCR1), exhibiting an IC50 of 4 nM. This compound effectively inhibits CCR1 signaling, making it valuable for studies exploring chemokine-related inflammatory processes and immune responses. Its application extends to research in various disease models, including autoimmune disorders and cancer. -
CCR Antagonist
BMS-753426 is a potent antagonist of the chemokine receptor CCR2. It effectively inhibits CCR2-mediated signaling, making it a valuable tool for research into inflammatory and autoimmune diseases. This compound is particularly relevant for studies investigating the role of chemokines in immune cell migration and related pathophysiological processes. -
CCR3 Antagonist
DPC-168 is a potent CCR3 antagonist with an IC50 of 41 nM. It demonstrates significant inhibition of eosinophil chemotaxis and is effective in reducing pulmonary inflammation. This compound is suitable for research applications targeting airway inflammation and related respiratory conditions. -
CCR-2 Antagonist
YJC-10592 is a potent orally active antagonist of the CCR-2 chemokine receptor. It selectively inhibits CCR-2 signaling, making it a valuable tool for investigating the role of this receptor in inflammatory processes. YJC-10592 is suitable for research applications related to asthma and idiopathic dermatitis, contributing to the understanding of disease mechanisms and potential therapeutic strategies. -
CCR5 Antagonist
CCR5 antagonist 4 is a potent oral antagonist of the CCR5 receptor. This compound exhibits significant biological activity by blocking CCR5-mediated signaling pathways, making it an important tool in the study of inflammatory diseases such as rheumatoid arthritis. Its application in research could provide insights into the modulation of immune responses and potential therapeutic strategies. -
CCR1 Antagonist
CCR1 antagonist 10 is a potent and orally bioavailable antagonist of the CCR1 receptor. It effectively inhibits the binding of 125I-MIP-1α to THP-1 cell membranes, demonstrating a Ki value of 2.3 nM. This compound is valuable for research applications involving inflammation, immune response modulation, and related signaling pathways. -
CCR8 Agonist
LMD-902 is a potent CCR8 agonist with an EC50 of 15 nM, demonstrating enhanced binding capacity influenced by critical residues such as PheVI:16. This compound is instrumental in researching inflammatory diseases, including bronchial asthma, as well as central nervous system disorders such as multiple sclerosis. Its specificity and efficacy make LMD-902 a valuable tool for advancing understanding in these therapeutic areas. -
CCR2 Antagonist
JNJ-17166864 is a highly selective CCR2 antagonist that demonstrates significant potential in modulating inflammatory responses. This compound has shown efficacy in reducing alveolar bone loss in a mouse model of periodontitis induced by Porphyromonas gingivalis infection. JNJ-17166864 is useful for research applications focused on inflammatory diseases, including allergic rhinitis and periodontal conditions. Its selectivity and biological activity make it a valuable tool for understanding CCR2-mediated pathways in these disease models. -
CCR2/CCR5 Antagonist
LUF8100 is a dual-target antagonist of CCR2 and CCR5, exhibiting pKi values of 5.23 for CCR2 and 4.97 for CCR5. This compound demonstrates significant potential in modulating immune responses and has relevance in cancer research, allowing for the investigation of immune homeostasis and potential therapeutic applications in pathologies driven by these chemokine receptors. -
CXCR2/CCR7 Antagonist
CXCR2/CCR7 antagonist-1 is a potent dual antagonist of the chemokine receptors CXCR2 and CCR7, exhibiting IC50 values of 0.0046 μM and 0.0014 μM, respectively. This compound serves as a valuable tool in the investigation of cancer metastasis and the mechanisms underlying autoimmune diseases, facilitating the study of therapeutic strategies targeting these pathways. Its efficacy in inhibiting both receptors makes it suitable for a range of biochemical and pharmacological research applications. -
CCR1 Antagonist
CP-481715 is a potent and selective antagonist of the CCR1 receptor, exhibiting a Kd of 9.2 nM for human CCR1. This compound demonstrates over 100-fold selectivity for CCR1 compared to a wide array of G-protein-coupled receptors, including related chemokine receptors. CP-481715 is primarily utilized in research related to rheumatoid arthritis and various inflammatory diseases, making it a valuable tool for investigating immune responses and therapeutic interventions in these conditions. -
CCR4 Antagonist
GSK-2239633 is a potent CCR4 antagonist that inhibits the chemokine receptor involved in the regulation of immune responses. This compound demonstrates significant biological activity in modulating T cell trafficking and has potential applications in asthma research and related inflammatory disorders. GSK-2239633 is valuable for studies focusing on immune modulation and therapeutic approaches for allergy and respiratory conditions. -
CCR3 Inhibitor
ALK4290 dihydrochloride is a potent inhibitor of the CCR3 receptor, exhibiting a Ki value of 3.2 nM for human CCR3. This compound demonstrates significant potential for modulating immune responses, making it a valuable tool in the study of neovascular age-related macular degeneration and Parkinson's disease. Researchers can utilize ALK4290 to investigate its effects on CCR3-related signaling pathways and its implications in various pathological conditions. -
CCR2 Inhibitor
ECL1i is an allosteric inhibitor targeting the CCR2 receptor. It selectively disrupts CCL2/CCR2-mediated chemotaxis, thereby impeding the recruitment of CCR2-positive cells. ECL1i has demonstrated efficacy in attenuating disease progression in models of experimental autoimmune encephalomyelitis, making it a valuable tool for studying autoimmune disease mechanisms and potential therapeutic interventions. -
CCR2 Antagonists
CCR2-RA is an allosteric antagonist of the chemokine (C-C motif) receptor 2 (CCR2). This compound selectively inhibits CCR2 signaling, making it a valuable tool in cancer research to explore the role of chemokine receptors in tumor progression and metastasis. Its application extends to investigating the modulation of immune responses in the tumor microenvironment. -
CCR1 Antagonist
BAY-3153 is a selective antagonist of the C-C motif chemokine receptor 1 (CCR1), with human IC50 values of 3 nM, rat IC50 of 11 nM, and mouse IC50 of 81 nM. This compound serves as a valuable tool for investigating the role of CCR1 in various biological processes, including inflammation and immune response modulation. Its specificity and potency make it suitable for research applications involving chemokine signaling and receptor activity. -
CCR8 Antagonist
SB-649701 is a potent antagonist of the human CCR8 receptor, exhibiting a pIC50 of 7.7. This compound is primarily utilized in research related to asthma, providing insights into inflammatory pathways and the role of CCR8 in immune responses. Its mechanism of action makes it valuable for exploring therapeutic strategies targeting airway hyperreactivity and allergic conditions. -
CCR2 Antagonist
BMS-741672 is a selective orally active antagonist of the CCR2 receptor, exhibiting an IC50 of 1.1 nM. This compound demonstrates over 700-fold selectivity for CCR2 compared to CCR5, making it a valuable tool for investigating the role of CCR2 in inflammatory processes. BMS-741672 has potential applications in studies of immune responses and related pathologies, contributing to the understanding of therapeutic strategies targeting chemokine signaling pathways. -
CCR3 Agonist
CH0076989 is a selective agonist of the CCR3 receptor that activates eosinophils and transfectants expressing both wild-type CCR3 and a CCR1:CCR3 chimeric receptor lacking the CCR3 amino-terminus. This compound exhibits a direct interaction with the transmembrane helices of CCR3; activity is abolished by mutations of key residues Y41, Y113, and E287. CH0076989 is ideal for research into inflammation and allergic diseases, including asthma, making it a valuable tool for understanding these pathological conditions. -
CCR2 Antagonist
RO5234444 is an orally active CCR2 antagonist with an IC50 of 22 nM for human CCR2 and 161 nM for mouse CCR2. This compound demonstrates significant biological activity by alleviating glomerulosclerosis, reducing albuminuria, and improving glomerular filtration rate (GFR) in the uninephrectomized type 2 diabetic db/db mouse model. RO5234444 serves as an essential tool for the investigation of type 2 diabetic nephropathy. -
CCR3 Antagonist
YM-344031 is a potent orally active antagonist targeting the CCR3 chemokine receptor. It effectively inhibits the binding of Eotaxin-1 and RANTES to CCR3 with IC50 values of 3.0 nM and 16.3 nM, respectively. This compound also reduces ligand-induced increases in intracellular calcium levels and chemotactic responses. Additionally, YM-344031 demonstrates the ability to ameliorate eotaxin-1-induced morphological changes in eosinophils from macaque blood and mitigates allergic skin responses in murine models, making it a valuable tool for research in allergic and inflammatory conditions. -
CCR1 Antagonist
CCR1 antagonist 12 is a selective antagonist of the CCR1 receptor, exhibiting an IC50 of 3 nM for human CCR1. This compound effectively inhibits CCL3-induced transwell chemotaxis, with an IC50 of 0.009 µM, making it a valuable tool for studying chemokine-mediated signaling pathways. Additionally, CCR1 antagonist 12 demonstrates favorable pharmacokinetic properties in rat models, supporting its potential use in preclinical research. -
CCR3 Antagonist
Maceneolignan H is a selective CCR3 antagonist, with an EC50 value of 1.4 μM. Isolated from the arils of Myristica fragrans, this neolignane compound demonstrates significant potential in the study of allergic diseases. Its ability to inhibit CCR3 suggests applications in researching therapeutic strategies for conditions mediated by this receptor. -
Ligand for CCR2
CCR2 ligand-1 is a potent ligand for the chemokine receptor CCR2, playing a crucial role in mediating inflammatory responses. This compound is valuable for studying CCR2 signaling pathways and its implications in diseases such as cancer and rheumatoid arthritis. Additionally, CCR2 ligand-1 can be utilized in the synthesis of LUF7996 when conjugated with Linker PIN1 degrader-3 and E3 ligase ligand Thalidomide 4-fluoride, facilitating research in targeted protein degradation. -
CCR3 Antagonist
BMS-639623 is a highly potent and orally bioavailable antagonist of the chemokine receptor CCR3, exhibiting an IC50 value of 0.3 nM. This compound demonstrates exceptional inhibitory activity against eosinophil chemotaxis, with an IC50 of 38 pM. BMS-639623 is primarily utilized in research focused on asthma and related inflammatory conditions. -
CCR3 Antagonist
CCR3 Antagonist 2 is a selective antagonist of the CCR3 receptor, a chemokine receptor involved in mediating inflammatory responses. This compound is particularly useful for research applications related to inflammatory and allergic conditions, including obstructive airways diseases. By interfering with CCR3 signaling, it allows for the exploration of therapeutic strategies aimed at modulating immune responses associated with these pathologies. -
CCR Antagonist
RAP-103 is a potent orally active CCR antagonist that targets the CCR pathway to provide synaptic protection. It effectively inhibits and reverses cytoskeletal alterations induced by PrPC/NOX signaling. RAP-103 is particularly relevant for research applications focused on Alzheimer's disease, offering insights into neuroprotective mechanisms and potential therapeutic strategies. -
CCR1 Inhibitor
BX-513 is a potent and selective antagonist of the CCR1 receptor. It effectively inhibits the binding of radiolabeled MIP-1α and RANTES to CCR1, with inhibition constants (Ki) of 40 nM and 60 nM, respectively. BX-513 demonstrates the ability to suppress MIP-1α-induced extracellular acidification, as well as MIP-1α- and RANTES-induced intracellular calcium mobilization and peripheral blood mononuclear cell migration. This compound is applicable in research focusing on autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. -
CCR2/CCR5 Antagonist
PF-4178903 is a potent dual antagonist of the chemokine receptors CCR2 and CCR5, exhibiting IC50 values of 3 nM and 5.3 nM, respectively. This orally active compound is valuable in the study of chronic inflammatory conditions and autoimmune diseases, providing insights into the modulation of immune responses. Its dual targeting capability makes PF-4178903 a significant tool for exploring therapeutic avenues in related research applications. -
CCR8 Agonist
LMD-584 is a selective agonist of CCR8, a chemokine receptor involved in immune responses and inflammation. This compound demonstrates significant biological activity in modulating CCR8 signaling pathways, making it a valuable tool for research applications focused on immune cell trafficking and related pathologies. LMD-584 may aid in understanding the role of CCR8 in various diseases, including cancer and autoimmune disorders. -
CCR5 Modulator
CCR5 modulator-1 is a selective modulator of the CCR5 chemokine receptor. This compound plays a significant role in the regulation of inflammatory processes and can be applied in research aimed at understanding various inflammatory diseases. Its use may provide insights into therapeutic strategies targeting CCR5-related pathways. -
Anti-CCR2 Antibody
Minokitug is a humanized monoclonal antibody that specifically targets the CCR2 protein. It exhibits significant biological activity by inhibiting CCR2-mediated signaling pathways, making it a valuable tool for studying inflammatory processes. This reagent is particularly relevant in research focused on refractory or relapsed ulcerative colitis, aiding in the understanding of the disease's pathophysiology and potential therapeutic interventions. -
CCR2 PROTAC Degrader
LUF7996 is a potent CCR2 PROTAC degrader that selectively targets and degrades CCR2 with a DC50 value of 2.6 μM. This compound effectively engages with the E3 ligase cereblon, promoting sustained and concentration-dependent degradation of CCR2 via the lysosomal pathway. LUF7996 is particularly valuable for research applications involving the inhibition of monocyte migration in vitro, facilitating studies in inflammation and immune response modulation. -
CCR1 Antagonist
cis-J-113863 is a competitive antagonist of chemokine receptor 1 (CCR1) that exhibits potent inhibitory effects, with IC50 values of 0.9 nM for human CCR1 and 5.8 nM for mouse CCR1. This compound is valuable for research in inflammation, immune response, and related therapeutic areas, facilitating the investigation of CCR1's role in various biological processes and disease models. -
CCR1 Antagonist
CCR1 antagonist 13 is a selective antagonist of the CCR1 chemokine receptor. This small molecule inhibitor effectively disrupts CCR1 signaling, making it a valuable tool for investigating the roles of CCR1 in inflammatory responses and immune cell migration. Its applications extend to research on autoimmune diseases, chronic inflammatory conditions, and the modulation of chemokine-mediated pathways. -
CCR2 Inhibitor-DOTA Conjugate
DOTA-ECL1i is a CCR2 inhibitor conjugated with DOTA, designed for use in positron emission tomography (PET) imaging. When radiolabeled with 68Ga, DOTA-ECL1i provides a specific PET tracer that targets CCR2 expression in various pathological conditions. This compound is applicable in research focused on pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, and cancers of the head, neck, and pancreas. -
CCR6/CXCR2 Antagonist
SQA1 is a squaramide derivative that functions as a CCR6 and CXCR2 antagonist, displaying a dissociation constant (Kd) of 250 nM. It effectively occupies the intracellular pocket, overlapping with the G protein binding site, which helps stabilize the closed conformation of the receptor. This compound is useful in research applications targeting chemokine receptor signaling pathways and their roles in inflammatory responses and immune cell trafficking.
